- Home
- IMMP vs REPL Comparison
IMMP vs REPL Comparison
Compare IMMP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- REPL
- Stock Information
- Founded
- IMMP 1987
- REPL 2015
- Country
- IMMP Australia
- REPL United States
- Employees
- IMMP N/A
- REPL N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- REPL Health Care
- Exchange
- IMMP Nasdaq
- REPL Nasdaq
- Market Cap
- IMMP 244.5M
- REPL 239.0M
- IPO Year
- IMMP N/A
- REPL 2018
- Fundamental
- Price
- IMMP $1.80
- REPL $6.94
- Analyst Decision
- IMMP Buy
- REPL Buy
- Analyst Count
- IMMP 1
- REPL 10
- Target Price
- IMMP $7.00
- REPL $8.25
- AVG Volume (30 Days)
- IMMP 69.1K
- REPL 19.8M
- Earning Date
- IMMP 02-27-2025
- REPL 08-11-2025
- Dividend Yield
- IMMP N/A
- REPL N/A
- EPS Growth
- IMMP N/A
- REPL N/A
- EPS
- IMMP N/A
- REPL N/A
- Revenue
- IMMP $3,019,249.00
- REPL N/A
- Revenue This Year
- IMMP $50.37
- REPL N/A
- Revenue Next Year
- IMMP N/A
- REPL $194.05
- P/E Ratio
- IMMP N/A
- REPL N/A
- Revenue Growth
- IMMP 24.11
- REPL N/A
- 52 Week Low
- IMMP $1.32
- REPL $2.68
- 52 Week High
- IMMP $2.72
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- IMMP 59.33
- REPL 46.35
- Support Level
- IMMP $1.60
- REPL $3.02
- Resistance Level
- IMMP $1.83
- REPL $8.07
- Average True Range (ATR)
- IMMP 0.05
- REPL 0.87
- MACD
- IMMP 0.02
- REPL -0.33
- Stochastic Oscillator
- IMMP 84.78
- REPL 40.29
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.